Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 11, Novembre 2006
Page(s) 947 - 952
Section M/S revues
DOI https://doi.org/10.1051/medsci/20062211947
Publié en ligne 15 novembre 2006
  1. Heitman J, Movva NR, Hall MN, et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253 : 905–9.
  2. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270 : 815–223.
  3. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005; 16 : 29–37.
  4. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth. Mol Cell 2002; 10 : 457–68.6.
  5. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124 :471–84.
  6. Schmelzle T, Tobias MN. MTOR : a central controller of cell growth. Cell 2000; 103 : 253–62.
  7. Gangloff YG, Mueller M, Dann SG, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004; 21 : 9508–16.
  8. Ruvinsky I, Sharon N, Lerer T, et al. Meyuhas ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005; 19 : 2199–211.
  9. Beretta L, Gingras AC, Svitkin YV, et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996; 15 : 658–6413.
  10. Harrington LS, Finlay GM, Lamb RF et al. Restraining PI3K : motor signalling goes back to the membrane. Trends Biochem Sci 2005; 30 : 35–4.
  11. Inoki K, Corradetti MN, Guan KL, et al. Dysregulation of the TSC mTOR pathway in human disease. Nat Genet 2005; 37 : 19–25.16.
  12. Kahan BD for the rapamune US study group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection : a randomised multicentre study. Lancet 2000; 356 : 194–20.
  13. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22 : 169–76.
  14. Eisen HJ, Tuzcu EM, Dorent R, et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 : 847–58.
  15. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349 : 1315–23.
  16. Bjornsti MA, Houghton PJ. The TOR pathway : a target for cancer therapy. Nat Rev Cancer 2004; 4 : 335–41.
  17. Chan S. Targeting the mammalian target of rapamycin (mTOR) : a new approach to treating cancer. Br J Cancer 2004; 91 : 1420–4.
  18. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779) in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23 : 5314–49.
  19. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22 : 909–18.
  20. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North central cancer treatment group study. Clin Oncol 2005; 10 : 5294–9.
  21. Panwalkar A, Verstovsek S, Gilles FJ. Mammalian target of rapamycin inhibition as therapy for hematological malignancies. Cancer 2004; 100 : 657–66.
  22. El-Hashemite N, Zhang H, Henske FD. Mutation in TSC-2 and actication of mammalian target of rapamycine signaling pathway in renal angiolipoma. Lancet 2003; 361 : 1346–9.
  23. Tao Y, Kim J, Schrier RW, et al. Rapamycine markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16 : 46–51.
  24. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combination. J Am Soc Nephrol 2001; 12 : 1059–66.
  25. Pallet N, Thervet E, Le Corre D, et al. SRL inhibits human epithelial cells proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int 2005; 67 : 2422–30.
  26. Letavernier E, Peraldi M, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80 : 1198–207.
  27. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidney. Am J Transplant 2005; 5 : 2441–5.
  28. Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 7 : 2063–72.
  29. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005; 27 : 476–82.
  30. Chueh SC, Kahan B. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 27 : 375–80.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.